Here are our top movers today. And don’t forget to join us in the Market Masters Trading Room.
And while you’re at it, check out Jason’s Back-to-School special below— only 47 seats remain — back to school equals more time for trading, hell ya!
FOCUS LIST🔎
ELAB – Up over 45% in the pre-market after announcing positive data results with completion of clinical study of Elevai Enfinity™ Topical Exosome Serum
TNXP – Up over 16% in pre after announcing collaboration with Bilthoven Biologicals on advancing development of Tonix’s Mpox Vaccine, TNX-801
GLPG – Up over 10% in pre after Ecor1 Capital reported a 9.9% stake in the company
*together with Vinovest
The Rising Demand for Whiskey: A Smart Investor’s Choice
Why are 250,000 Vinovest customers investing in whiskey?
In a word – consumption.
Global alcohol consumption is on the rise, with projections hitting new peaks by 2028. Whiskey, in particular, is experiencing significant growth, with the number of US craft distilleries quadrupling in the past decade. Younger generations are moving from beer to cocktails, boosting whiskey’s popularity.
That’s not all.
Whiskey’s tangible nature, market resilience, and Vinovest’s strategic approach make whiskey a smart addition to any diversified portfolio.
HOTLIST🔥
ELAB – Up over 45% in the pre-market after announcing positive data results with completion of clinical study of Elevai Enfinity™ Topical Exosome Serum
Elevai Labs Inc. (ELAB) is a skincare development company, designs, manufactures, and markets skincare products in the United States. The company offers Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions.
In the pre-market this morning, the company announced the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance.
The data, pending peer review, from the clinical study was internally reviewed by the Company, and the results show Elevai enfinity™ to be safe and tolerable with significant improvement noted across many aspects of skin appearance. Elevai aims to publish the full study results in the near future.
The stock traded up over 45% in the pre-market in reaction to the news.
The $0.34 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $0.37, $0.40, $0.45 and then $0.51.
Below $0.34, targets to the downside are $0.32, $0.30, $0.28 and then a gap fill at $0.3070 with $0.2509 below that.
TNXP – Up over 16% in pre after announcing collaboration with Bilthoven Biologicals on advancing development of Tonix’s Mpox Vaccine, TNX-801
Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company that focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering.
In the pre-market this morning, the company announced a collaboration with Bilthoven Biologicals to advance TNX-801, Tonix’s mpox vaccine candidate. TNX-801 (recombinant horsepox virus) is a live replicating, attenuated virus vaccine based on horsepox in preclinical development to prevent mpox and smallpox.
BBio is a Netherlands-based end-to-end vaccine manufacturer of viral and bacterial vaccines.
Shares of TNXP traded up over 16% in the pre-market in reaction to the news.
The first targets to the upside are prior resistance at $0.3770, and then the pre-market high at $0.39. Beyond that, $0.4150, $0.45 and $0.4850 come into play.
Below $0.3770, targets to the downside are $0.37, $0.36, $0.35 and then a gap fill at $0.34.
HURRY!!!
Jason went 19-for-19 last week…
His $2,000 account is up to $30,610 – can he reach $100,000???*
Only one way to find out and see every trade he makes…
Join the Small Account Journey for 60% off right now!
Only 100 47 seats remain
Use coupon code: SAVE60 (hit APPLY)
The coupon lowers $1,497 yearly to $598 grandfathered
Or $2,497 for a 5 year membership to $998 [BEST DEAL]
*Trading is hard, results not guaranteed and should not be expected to be replicated typically.
GLPG – Up over 10% in pre after Ecor1 Capital reported a 9.9% stake in the company
Galapagos NV is a biotechnology company that develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Overnight, Ecor1 Capital reported a 9.9% stake in the company and GLPG is trading up over 10% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $28.89.
Beyond that, targets to the upside are $29.50, $30, $30.60 and then $32.
Below $28.89, targets to the downside are $28.59, $28, $27.50 and then $26.
MARKET NEWS 📰
P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!
Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
